Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors

Saturday, July 19, 2008 General News J E 4
ANN ARBOR, Mich., July 18 Velcura Therapeutics, Inc. CEOMichael Long, Ph.D., announced that William F. Brinkerhoff has joined theBoard of Directors of the biotechnology company, which completed afirst-in-man clinical trial for VEL-0230, a powerful anti-inflammatory agentstimulating bone formation and inhibiting bone loss. Velcura is investigatingits lead compound as a treatment for rheumatoid arthritis and other bonediseases.

Bill Brinkerhoff is the chief operating officer of Cerenis Therapeutics,which is focused on the discovery, development and commercialization ofbreakthrough HDL-related therapies for the treatment of cardiovascular andmetabolic diseases.

"In joining Velcura's Board, I look forward to assisting them in theirmission of developing therapies that restore bone health," said BillBrinkerhoff.

Before founding Cerenis in 2005, Brinkerhoff was vice president ofbusiness development for Esperion Therapeutics in Ann Arbor, where hesuccessfully negotiated multiple large potential partnering agreements priorto Esperion's acquisition by Pfizer. Before joining Esperion in 2002, he wasthe director of business development and director of market planning and salesoperations, for Sankyo Parke Davis in Parsippany, New Jersey.

A graduate of the University of Michigan, Brinkerhoff earned his Master ofBusiness Administration with Distinction in 1989. He also has bachelor's andmaster's degrees in Industrial Engineering and Operations Research from U-M'sCollege of Engineering.

Velcura's other directors are Michael W. Long and Bill Orobone, CEO ofSyneptics, an alternative energy financing entity.

About Velcura Therapeutics, Inc.

Velcura Therapeutics, Inc. is an early stage biotechnology companyheadquartered in Ann Arbor, Michigan. Velcura's research focus is tounderstand human bone disease and to discover novel therapeutics that restorebone health. Velcura develops highly differentiated therapies for bonedisease; specifically, therapies that restore the balance between bonebuilding and bone loss activities in a single molecule. Velcura uses itspatented platform technologies to discover and optimize these compounds. Moreinformation is at .Available Topic Expert(s): For information on the listed expert(s), clickappropriate link.Michael W. Long, Ph.D.

SOURCE Velcura Therapeutics, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
minSURG(TM) Corporation Launches International Div...
Video: Trinity Mother Frances and Texas Oncology-T...